NYSE:IGC
IGC Pharma, Inc.
IGC Pharma, Inc.'s revenue fell 5.5% in fiscal 2025 to $1.3M while operating margin rose to −585.8%. Free cash flow was −$4.9M, −386.1% of revenue, and the diluted share count rose 30.0%.Summary generated from IGC Pharma, Inc.'s SEC filings. Latest annual report filed Jun 27, 2025.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$1.3M
Revenue growth−5.5%
Revenue, 5-yr CAGR−20.8%
Gross margin48.7%
Operating margin−585.8%
Net margin−560.3%
ROIC−95.5%
Return on equity−104.3%
Debt / equity0.02
Free cash flow−$4.9M
FCF margin−386.1%
Share count change+30.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 | 0 | 1 | 1 | 1 |
| Operating income | −9 | −15 | −12 | −10 | −7 |
| Net income | −9 | −15 | −12 | −13 | −7 |
| Free cash flow | −12 | −8 | −7 | −5 | −5 |
Recent filings
- 4Insider transaction report
Sep 29, 2026 - 4Insider transaction report
Sep 29, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KRegulation FD disclosure
Jul 14, 2026 - 8-KEntry into a material agreement
Jul 6, 2026 - 8-KEntry into a material agreement
Jun 8, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 15, 2026 - 8-KEntry into a material agreement
Apr 20, 2026